Lack of association of tumor necrosis factor superfamily member 4 (TNFSF4) gene polymorphisms (rs3850641 and rs17568) with coronary heart disease and stroke: A systematic review and meta-analysis.

OBJECTIVE:To evaluate the association between the tumor necrosis factor superfamily member 4 (TNFSF4) gene polymorphisms and common cardiovascular and cerebrovascular diseases. METHODS:A literature-based search was conducted through databases including PubMed, EMBASE, Cochrane Library, CNKI, and WanFang data. Crude odds ratios (ORs) and 95% confidence intervals (CI) were calculated to estimate the strength of the association between TNFSF4 polymorphisms (rs3850641 and rs17568) and the risk of coronary heart disease (CHD) and stroke. RESULTS:Overall, 11 eligible studies were included in this meta-analysis. G allele was showed not to be associated with CHD and stroke, compared with A allele (rs3850641: OR=1.02, 95% CI=0.89-1.17; rs17568: OR=1.09, 95% CI=0.89-1.33). Genotypic analysis demonstrated that there was no significant association between the risk of CHD and stroke and rs3850641 [homozygous comparison (GG vs. AA): OR=1.05, 95% CI=0.74-1.50; heterozygous comparison (GA vs. AA): OR=1.00, 95% CI=0.88-1.13; recessive model (GG vs. GA+AA): OR=1.04, 95% CI=0.76-1.43; dominant model (GG+GA vs. AA): OR=1.01, 95% CI=0.88-1.17]. Similarly, no susceptibility between CHD and stroke and rs17568 polymorphism was uncovered (GG vs. AA: OR=1.04, 95% CI=0.74-1.46; GA vs. AA: OR=1.07, 95% CI=0.62-1.83; GG+GA vs. AA: OR=1.13, 95% CI=0.82-1.56; GG vs. GA+AA: OR=1.01, 95% CI=0.74-1.39). CONCLUSION:The present study demonstrated that there is no significant relationship between TNFSF4 gene polymorphism and cerebrovascular and cardiovascular diseases.